Nisha Marathe
Directeur/Membre du Conseil chez Soteria Biotherapeutics, Inc.
Postes actifs de Nisha Marathe
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Roche Ventures
 Roche Ventures Investment ManagersFinance Roche Ventures is the venture investment division of the pharmaceutical company F. Hoffmann-La Roche Ltd., which is a subsidiary of Roche Holding AG (SWX:ROG). The group is headquartered in Basel with operations and affiliates worldwide, and is a world leader in pharmaceuticals and diagnostics. The firm was founded in 2002. | Private Equity Investor | 01/01/2018 | - |
| Analyste en capital-investissement | 01/03/2016 | 01/01/2018 | |
Soteria Biotherapeutics, Inc.
 Soteria Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Soteria Biotherapeutics, Inc. develops next-generation immunotherapies. Its development allows to control the activity of immunomodulatory therapeutics such as bi-specific T-cell engagers (BiTEs) and CAR T-cells.The company was founded by Zachary Hill and Alexander Martinko and is headquartered in San Francisco, CA. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Nisha Marathe
Statistiques
Internationale
| Suisse | 2 |
| Etats-Unis | 2 |
Opérationnelle
| Private Equity Analyst | 1 |
| Private Equity Investor | 1 |
| Director/Board Member | 1 |
Sectorielle
| Finance | 2 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Roche Ventures
Roche Ventures Investment ManagersFinance Roche Ventures is the venture investment division of the pharmaceutical company F. Hoffmann-La Roche Ltd., which is a subsidiary of Roche Holding AG (SWX:ROG). The group is headquartered in Basel with operations and affiliates worldwide, and is a world leader in pharmaceuticals and diagnostics. The firm was founded in 2002. | Finance |
Soteria Biotherapeutics, Inc.
Soteria Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Soteria Biotherapeutics, Inc. develops next-generation immunotherapies. Its development allows to control the activity of immunomodulatory therapeutics such as bi-specific T-cell engagers (BiTEs) and CAR T-cells.The company was founded by Zachary Hill and Alexander Martinko and is headquartered in San Francisco, CA. | Health Technology |
- Bourse
- Insiders
- Nisha Marathe
- Expérience
